Literature DB >> 27349371

Kidney cancer: Finding a niche for girentuximab in metastatic renal cell carcinoma.

Sumanta K Pal1, Neeraj Agarwal2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27349371     DOI： 10.1038/nrurol.2016.115

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

2.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

Authors:  Robert J Motzer; Thomas E Hutson; Hilary Glen; M Dror Michaelson; Ana Molina; Timothy Eisen; Jacek Jassem; Jakub Zolnierek; Jose Pablo Maroto; Begoña Mellado; Bohuslav Melichar; Jiri Tomasek; Alton Kremer; Han-Joo Kim; Karen Wood; Corina Dutcus; James Larkin
Journal:  Lancet Oncol       Date:  2015-10-22       Impact factor: 41.316

3.  The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

Authors:  David F McDermott; Su-Chun Cheng; Sabina Signoretti; Kim A Margolin; Joseph I Clark; Jeffrey A Sosman; Janice P Dutcher; Theodore F Logan; Brendan D Curti; Marc S Ernstoff; Leonard Appleman; Michael K K Wong; Nikhil I Khushalani; Leslie Oleksowicz; Ulka N Vaishampayan; James W Mier; David J Panka; Rupal S Bhatt; Alexandra S Bailey; Bradley C Leibovich; Eugene D Kwon; Fairooz F Kabbinavar; Arie S Belldegrun; Robert A Figlin; Allan J Pantuck; Meredith M Regan; Michael B Atkins
Journal:  Clin Cancer Res       Date:  2014-11-25       Impact factor: 12.531

4.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.

Authors:  Matthew H T Bui; David Seligson; Ken-ryu Han; Allan J Pantuck; Frederick J Dorey; Yunda Huang; Steve Horvath; Bradley C Leibovich; Shefali Chopra; Shu-Yuan Liao; Eric Stanbridge; Michael I Lerman; Aarno Palotie; Robert A Figlin; Arie S Belldegrun
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

5.  Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.

Authors:  Alexander B Stillebroer; Otto C Boerman; Ingrid M E Desar; Marije J Boers-Sonderen; Carla M L van Herpen; Johannes F Langenhuijsen; Peter M Smith-Jones; Egbert Oosterwijk; Wim J G Oyen; Peter F A Mulders
Journal:  Eur Urol       Date:  2012-08-21       Impact factor: 20.096

6.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

7.  Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.

Authors:  Constantijn H J Muselaers; Marye J Boers-Sonderen; Tim J van Oostenbrugge; Otto C Boerman; Ingrid M E Desar; Alexander B Stillebroer; Sasja F Mulder; Carla M L van Herpen; Johan F Langenhuijsen; Egbert Oosterwijk; Wim J G Oyen; Peter F A Mulders
Journal:  Eur Urol       Date:  2015-12-23       Impact factor: 20.096

8.  Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.

Authors:  Grant D Stewart; Fiach C O'Mahony; Alexander Laird; Sukaina Rashid; Sarah A Martin; Lel Eory; Alexander L R Lubbock; Jyoti Nanda; Marie O'Donnell; Alan Mackay; Peter Mullen; S Alan McNeill; Antony C P Riddick; Michael Aitchison; Daniel Berney; Axel Bex; Ian M Overton; David J Harrison; Thomas Powles
Journal:  Eur Urol       Date:  2014-05-10       Impact factor: 20.096

Review 9.  Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis.

Authors:  Simon J A van Kuijk; Ala Yaromina; Ruud Houben; Raymon Niemans; Philippe Lambin; Ludwig J Dubois
Journal:  Front Oncol       Date:  2016-03-29       Impact factor: 6.244
  9 in total
  8 in total

Review 1.  Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma.

Authors:  Rebeca Osca-Verdegal; Jesús Beltrán-García; José Luis Górriz; José María Martínez Jabaloyas; Federico V Pallardó; José Luis García-Giménez
Journal:  Front Cell Dev Biol       Date:  2022-06-22

2.  An update on anticancer drug development and delivery targeting carbonic anhydrase IX.

Authors:  Justina Kazokaitė; Ashok Aspatwar; Seppo Parkkila; Daumantas Matulis
Journal:  PeerJ       Date:  2017-11-23       Impact factor: 2.984

3.  Hydrogen-deuterium exchange mass spectrometry reveals three unique binding responses of mAbs directed to the catalytic domain of hCAIX.

Authors:  Joey G Sheff; John F Kelly; Anna Robotham; Traian Sulea; Félix Malenfant; Denis L'Abbé; Mélanie Duchesne; Alex Pelletier; Jean Lefebvre; Andrea Acel; Marie Parat; Mylene Gosselin; Cunle Wu; Yves Fortin; Jason Baardsnes; Henk Van Faassen; Shannon Awrey; Shawn C Chafe; Paul C McDonald; Shoukat Dedhar; Anne E G Lenferink
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

4.  Construction and Verification of a Combined Hypoxia and Immune Index for Clear Cell Renal Cell Carcinoma.

Authors:  Bin Wang; Lixiao Liu; Jinting Wu; Xiaolu Mao; Zhen Fang; Yingyu Chen; Wenfeng Li
Journal:  Front Genet       Date:  2022-02-09       Impact factor: 4.599

5.  Compound C Inhibits Renca Renal Epithelial Carcinoma Growth in Syngeneic Mouse Models by Blocking Cell Cycle Progression, Adhesion and Invasion.

Authors:  Myungyeon Lee; Na Yeon Ham; Chi Yeon Hwang; Jiwon Jang; Boram Lee; Joo-Won Jeong; Insug Kang; Eui-Ju Yeo
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

6.  circPRRC2A promotes angiogenesis and metastasis through epithelial-mesenchymal transition and upregulates TRPM3 in renal cell carcinoma.

Authors:  Wei Li; Feng-Qiang Yang; Chen-Min Sun; Jian-Hua Huang; Hai-Min Zhang; Xue Li; Guang-Chun Wang; Ning Zhang; Jian-Ping Che; Wen-Tao Zhang; Yang Yan; Xu-Dong Yao; Bo Peng; Jun-Hua Zheng; Min Liu
Journal:  Theranostics       Date:  2020-03-15       Impact factor: 11.556

Review 7.  Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy.

Authors:  Ying Wang; Yunjing Zhang; Ping Wang; Xianghui Fu; Weiqiang Lin
Journal:  Mol Cancer       Date:  2020-10-14       Impact factor: 27.401

Review 8.  Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management.

Authors:  Jean Courcier; Alexandre de la Taille; Maya Nourieh; Ingrid Leguerney; Nathalie Lassau; Alexandre Ingels
Journal:  Int J Mol Sci       Date:  2020-09-28       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.